Market Overview

Pfizer Receives European Approval to Expand Use of Prevenar 13


Pfizer Inc. (NYSE: PFE) announced today the company's pneumococcal
conjugate vaccine, Prevenar 13* (pneumococcal polysaccharide conjugate
vaccine [13-valent, adsorbed]), received European approval for an
expanded indication to include adults aged 18 to 49 years for active
immunization for the prevention of invasive disease caused by
vaccine-type Streptococcus pneumoniae (S. pneumoniae).1
Previously approved in the European Union (EU) for use in infants, young
children and adolescents aged 6 weeks to 17 years, as well as adults 50
years of age and older, Prevenar 13 is now the only pneumococcal vaccine
in the EU that offers protection against invasive disease from infancy
through adulthood.1 The European Commission is the first to
approve Prevenar 13 to offer protection against invasive disease at all

See full press release

Posted-In: News Guidance Contracts Asset Sales Global


Related Articles (PFE)

View Comments and Join the Discussion!

Partner Center